A citation-based method for searching scientific literature

Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li. Cancer Discov 2020
Times Cited: 98



Shanu Modi, Haeseong Park, Rashmi K Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern, Ian E Krop, Caleb Lee, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Shunji Takahashi. J Clin Oncol 2020
Times Cited: 148




List of shared articles



Times cited

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa,[...]. Clin Cancer Res 2021
2

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Jose Perez, Laia Garrigós, Maria Gion, Pasi A Jänne, Kohei Shitara, Salvatore Siena, Javier Cortés. Expert Opin Biol Ther 2021
4


Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori,[...]. Clin Cancer Res 2021
2

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse,[...]. Future Oncol 2022
0

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Alice Indini, Erika Rijavec, Francesco Grossi. Int J Mol Sci 2021
7

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez,[...]. Lancet Oncol 2021
45

Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.
Jacob J Kennedy, Jeffrey R Whiteaker, Laura C Kennedy, Dustin E Bosch, Melissa L Lerch, Regine M Schoenherr, Lei Zhao, ChenWei Lin, Shrabanti Chowdhury, Mark R Kilgore,[...]. Clin Chem 2021
2

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo. Nat Rev Clin Oncol 2022
14

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.
Ibrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari, Misako Nagasaka. Lung Cancer (Auckl) 2021
0

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.
Rupert Bartsch, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Andreas Petzer, Marija Balic, Ursula Pluschnig, Thamer Sliwa, Christian Singer. Wien Klin Wochenschr 2022
0

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Xinling Zhang, Andrew C Huang, Fahai Chen, Hu Chen, Lele Li, Nana Kong, Wenting Luo, Jianmin Fang. Antib Ther 2022
1